From The Corner Lab - Blog Posts

Virginia Law Is Nation’s First Dealing With Substitution of Biosimilars

Posted by Jim Menoutis on Fri, Apr 05, 2013 @ 11:32 AM

A new Virginia law is the first in the country that would prevent the automatic substitution of non-interchangeable biosimilars. Pharmacists substituting an interchangeable biosimilar for a brand product would need to inform the patient prior to the switch. Amgen and Genentech have been pushing state legislators to enact measures, including Virginia’s H.B. 1422, but the generic industry says such rules will create hurdles for the uptake of biosimilars.

Read More

Topics: biologic drug generic drug, branded drug, Biosimilars